Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
CN |
|
Valiant Co Ltd
SZSE:002643
|
CN |
|
Haisco Pharmaceutical Group Co Ltd
SZSE:002653
|
CN |
|
A
|
AES Andes SA
SGO:AESANDES
|
CL |
|
Kailong High Technology Co Ltd
SZSE:300912
|
CN |
|
Choice International Ltd
NSE:CHOICEIN
|
IN |
|
Elanco Animal Health Inc
NYSE:ELAN
|
US |
|
C
|
Cargotec Corp
OMXH:CGCBV
|
FI |
|
Ferrexpo PLC
LSE:FXPO
|
CH |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
CN |
|
Duckhorn Portfolio Inc
NYSE:NAPA
|
US |
|
Sihui Fuji Electronics Technology Co Ltd
SZSE:300852
|
CN |
Hangzhou Tigermed Consulting Co Ltd
Founded in 2004, Hangzhou Tigermed Consulting Co., Ltd. emerged as a pivotal player in the flourishing landscape of clinical research services within the pharmaceutical and biotechnology sectors. As a leading contract research organization (CRO), Tigermed has meticulously woven a fabric of comprehensive solutions that span from drug development to clinical trial management. Their expertise extends across various therapeutic areas, underpinning a business model that thrives on facilitating the intricate process through which innovative drugs make their way from concept to market. The company’s robust portfolio of services encompasses clinical operations, regulatory submissions, data management, and biostatistics, effectively addressing the myriad needs of drug development companies looking to streamline operations and accelerate time-to-market.
Tigermed’s revenue model primarily revolves around contracts and partnerships with pharmaceutical and biotech companies seeking external expertise in clinical trials. The company's proficiency in managing multinational projects, especially within China and the broader Asia-Pacific region, provides an edge in a competitive global market that increasingly values speed and localized knowledge. Rather than merely providing traditional consulting services, Tigermed capitalizes on cutting-edge technology and a deep understanding of regional regulatory frameworks to offer a seamless and efficient trial process. In doing so, it captures the growing demand for outsourcing drug development work, ensuring steady revenue streams while solidifying its status as a vital partner in the relentless pursuit of medical innovation.
Founded in 2004, Hangzhou Tigermed Consulting Co., Ltd. emerged as a pivotal player in the flourishing landscape of clinical research services within the pharmaceutical and biotechnology sectors. As a leading contract research organization (CRO), Tigermed has meticulously woven a fabric of comprehensive solutions that span from drug development to clinical trial management. Their expertise extends across various therapeutic areas, underpinning a business model that thrives on facilitating the intricate process through which innovative drugs make their way from concept to market. The company’s robust portfolio of services encompasses clinical operations, regulatory submissions, data management, and biostatistics, effectively addressing the myriad needs of drug development companies looking to streamline operations and accelerate time-to-market.
Tigermed’s revenue model primarily revolves around contracts and partnerships with pharmaceutical and biotech companies seeking external expertise in clinical trials. The company's proficiency in managing multinational projects, especially within China and the broader Asia-Pacific region, provides an edge in a competitive global market that increasingly values speed and localized knowledge. Rather than merely providing traditional consulting services, Tigermed capitalizes on cutting-edge technology and a deep understanding of regional regulatory frameworks to offer a seamless and efficient trial process. In doing so, it captures the growing demand for outsourcing drug development work, ensuring steady revenue streams while solidifying its status as a vital partner in the relentless pursuit of medical innovation.